10 Best High-Risk Penny Stocks to Buy Right Now

7. Ocugen, Inc. (NASDAQ:OCGN)

Ocugen, Inc. (NASDAQ:OCGN) released its fourth-quarter fiscal 2025 results on March 4. The company reported research and development expenses of $10.7 million for the quarter. General and administrative costs came in at $6.1 million. For the quarter, net loss per common share reached $0.06. Research and development expenses for the full year totalled $39.8 million, while general and administrative expenses were $27.6 million. Net loss per share for the year was reported at $0.23.

Ocugen, Inc. (NASDAQ:OCGN) also stated that its cash and cash equivalents are expected to support operations into the fourth quarter of 2026. A possible extension into the second quarter of 2027 could be achieved if warrants are exercised.

The company reaffirmed its target of filing three Biologics License Applications (BLAs) over the next three years. According to the CEO, Shankar Musunuri, Ocugen, Inc. (NASDAQ:OCGN) remains on track to begin a rolling BLA submission in the third quarter of 2026, with commercialization of OCU400 expected in 2027. Looking ahead, topline Phase II/III data for OCU410ST are expected in the second quarter of 2027, after which the company plans to move forward with a BLA submission. The phase III trial for OCU410 is projected to start in 2026, with full Phase II data for OCU410 set to be reported this month.

Ocugen, Inc. (NASDAQ:OCGN) is a biopharmaceutical company. The company is engaged in the development, discovery, and commercialization of biologics, innovative gene and cell therapies, and vaccines aimed at enhancing patient health. It was incorporated in 2013 and is based in Malvern, Pennsylvania.